Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.
Speaker 2: (
00:32)
Could you provide a brief background about yourself?
Speaker 2: (
01:12)
Would you give us an overview of the PM3CX test?
Speaker 2: (
03:02)
Which patients should have this testing?
Speaker 2: (
05:14)
Is this test qualitative and RNA?
Speaker 2: (
06:35)
After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin?
Speaker 2: (
08:09)
For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations?
Are there any other insights about this test that you'd like to share?